14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NOVTU vs ABSI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Absci Corporation (ABSI) is the stronger overall head-to-head candidate over NOVTU (NOVTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NOVTU carries a Unified Composite Score of 42.5/100 (HOLD) at $50.76 (N/M Forward P/E, N/A operating margin), whereas ABSI carries 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin).
Composite vs. Pillar Nuance: While NOVTU currently prints a higher short-term Unified Composite Score (42.5/100 HOLD vs. ABSI 37.5/100 SELL), ABSI captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-9108.3% vs. N/A operating margin) and revenue trajectory (-19.6% vs. N/A YoY).
Technical & Structure Timing Caution: NOVTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NOVTU vs ABSI. Trailing 12-month operating profitability (NOVTU N/A vs ABSI -9108.3%) and valuation multiples (NOVTU N/M vs ABSI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.6B market capitalization and -9108.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NOVTU vs ABSI Key Questions & Quantitative Answers
As of Nov 16, 2026, Absci Corporation (ABSI) is the stronger overall head-to-head candidate over NOVTU (NOVTU) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NOVTU carries a Unified Composite Score of 42.5/100 (HOLD) at $50.76 (N/M Forward P/E, N/A operating margin), whereas ABSI carries 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin). Composite vs. Pillar Nuance: While NOVTU currently prints a higher short-term Unified Composite Score (42.5/100 HOLD vs. ABSI 37.5/100 SELL), ABSI captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-9108.3% vs. N/A operating margin) and revenue trajectory (-19.6% vs. N/A YoY). Technical & Structure Timing Caution: NOVTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.1); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABSI leads the Growth & Scale pillar: NOVTU posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABSI at -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin). On trailing 12-month operating scale, NOVTU generates N/A in USD-normalized revenue versus $1.5M for ABSI. In operating R&D and SG&A reinvestment, NOVTU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABSI.
NOVTU and ABSI trade at balanced relative valuation multiples. NOVTU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NOVTU (N/A ROE) versus ABSI (-58.6% ROE) capital efficiency.
In options market volatility and institutional positioning, NOVTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.70β · 65% Vol realized risk). By comparison, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.31β · 126% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.